Abstract
In this issue of Blood, Arezes and colleagues present new and exciting evidence that erythropoietin (EPO) suppresses bone morphogenetic protein (BMP)-mediated signaling in an erythroferrone (ERFE)-dependent mechanism and ERFE in turn interferes with the binding of a specific set of BMPs to their receptors.1 These findings represent a breakthrough in the understanding of how EPO and ERFE function to decrease hepcidin expression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1463-1464 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 132 |
| Issue number | 14 |
| DOIs | |
| State | Published - Oct 4 2018 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology